Company intelligence / Profile preview

Bioxodes

Ownership: Private
Development stage: Phase 2

Overview

Bioxodes’ lead candidate, BIOX‑101 (Ir-CPI), demonstrated positive interim results in a Phase IIa trial for intracerebral hemorrhage. The drug showed safety and encouraging efficacy signals—reducing hematoma and edema volume with no increase in bleeding risk or serious adverse events. Enrollment was stopped early due to meeting endpoints, and the company plans to initiate a potentially registrational Phase IIb study in the first half of 2027[2].

Therapeutic areas: ImmunologyCardiovascularNeurology
Modalities: Peptide/protein therapeutics (derived from tick salivary proteins)
Industry: Biotech

Drug pipeline

1 asset

BIOX-101

Partnerships

No major pharmaceutical partnerships disclosed as of May 2025. Academic collaborations are noted below.

Beyond the preview

Go deeper on Bioxodes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioxodes.

Explore the full profile